Effect of Secukinumab on Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: a Post hoc Analysis of the SUPREME Study

Acta Dermato Venereologica ◽

10.2340/00015555-3712 ◽

2020 ◽

pp. 0

Author(s):

M Talamonti ◽

G Malara ◽

Y Natalini ◽

F Bardazzi ◽

A Conti ◽

...

Keyword(s):

Severe Psoriasis ◽

Anxiety And Depression ◽

Post Hoc Analysis ◽

Download Full-text

26581 Maintenance of complete skin clearance throughout 3 years of continuous guselkumab treatment in patients with moderate-to-severe psoriasis: A post hoc analysis of 5-year data from the VOYAGE 1 trial

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2021.06.449 ◽

2021 ◽

Vol 85 (3) ◽

pp. AB108

Author(s):

Antonio Costanzo ◽

Curdin Conrad ◽

Talia Gramiccia ◽

Maria Jazra ◽

Elke M.G. J. de Jong ◽

...

Keyword(s):

Severe Psoriasis ◽

Post Hoc Analysis ◽

Download Full-text

Maintenance of response to brodalumab at 52 weeks among patients with moderate-to-severe psoriasis: Post hoc analysis of two phase 3 studies

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2018.05.749 ◽

2018 ◽

Vol 79 (3) ◽

pp. AB185

Keyword(s):

Severe Psoriasis ◽

Phase 3 ◽

Two Phase ◽

Post Hoc Analysis ◽

Download Full-text

Effect of adalimumab treatment on pruritus: A post-hoc analysis of the phase III, randomized REVEAL trial in patients with moderate to severe psoriasis

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2012.12.818 ◽

2013 ◽

Vol 68 (4) ◽

pp. AB198

Keyword(s):

Severe Psoriasis ◽

Phase Iii ◽

Post Hoc Analysis ◽

Adalimumab Treatment ◽

Download Full-text

13677 Time to relapse in patients with moderate to severe psoriasis who were tildrakizumab responders at week 28: Post hoc analysis through 64 weeks from the reSURFACE 1 trial

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2020.06.131 ◽

2020 ◽

Vol 83 (6) ◽

pp. AB11

Author(s):

Kristian Reich ◽

José-Manuel Carrascosa ◽

Emilio Fumero ◽

Andreu Schoenenberger López ◽

Mark Lebwohl

Keyword(s):

Severe Psoriasis ◽

Post Hoc Analysis ◽

Time To Relapse ◽

Download Full-text

Time to relapse after tildrakizumab withdrawal in patients with moderate‐to‐severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial

Journal of the European Academy of Dermatology and Venereology ◽

10.1111/jdv.16964 ◽

2020 ◽

Author(s):

R.B. Warren ◽

J.M. Carrascosa ◽

E. Fumero ◽

A. Schoenenberger ◽

M.G. Lebwohl ◽

...

Keyword(s):

Severe Psoriasis ◽

Post Hoc Analysis ◽

Time To Relapse ◽

Download Full-text

25800 Bimekizumab for the treatment of moderate to severe psoriasis of the scalp: Post hoc analysis from the BE SURE phase 3 trial

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2021.06.307 ◽

2021 ◽

Vol 85 (3) ◽

pp. AB70

Author(s):

Kristian Reich ◽

Joseph F. Merola ◽

Boni Elewski ◽

Kim A. Papp ◽

Luis Puig ◽

...

Keyword(s):

Severe Psoriasis ◽

Phase 3 ◽

Post Hoc Analysis ◽

Download Full-text

26874 Long-term efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who were partial responders or nonresponders to etanercept: Post hoc analysis through 5 years from the reSURFACE 2 phase 3 trial

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2021.06.496 ◽

2021 ◽

Vol 85 (3) ◽

pp. AB119

Author(s):

Diamant Thaçi ◽

Christopher E.M. Griffiths ◽

Lars Iversen ◽

Andrea Peserico ◽

Ignasi Pau-Charles ◽

...

Keyword(s):

Severe Psoriasis ◽

Efficacy And Safety ◽

Phase 3 ◽

Post Hoc Analysis ◽

Term Efficacy ◽

Download Full-text

Dupilumab Improves Symptoms of Anxiety and Depression in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of Three Phase 3 Trials (LIBERTY AD SOLO 1 & 2 and ADOL)

Journal of Allergy and Clinical Immunology ◽

10.1016/j.jaci.2019.12.268 ◽

2020 ◽

Vol 145 (2) ◽

pp. AB191

Author(s):

Jonathan Silverberg ◽

Weily Soong ◽

Benjamin Lockshin ◽

Abhijit Gadkari ◽

Zhen Chen ◽

...

Keyword(s):

Atopic Dermatitis ◽

Anxiety And Depression ◽

Severe Atopic Dermatitis ◽

Phase 3 ◽

Post Hoc Analysis ◽

Three Phase ◽

Download Full-text

Efficacy of ixekizumab on nail psoriasis in pediatric patients with moderate‐to‐severe psoriasis: a post‐hoc analysis from IXORA‐PEDS

Journal of the European Academy of Dermatology and Venereology ◽

10.1111/jdv.17564 ◽

2021 ◽

Author(s):

M M B Seyger ◽

A Reich ◽

C El Baou ◽

C Schuster ◽

E Riedl ◽

...

Keyword(s):

Pediatric Patients ◽

Severe Psoriasis ◽

Nail Psoriasis ◽

Post Hoc Analysis ◽

Download Full-text

Association of a prehabilitation program with anxiety and depression before colorectal surgery: a post hoc analysis of the pERACS randomized controlled trial

Langenbeck s Archives of Surgery ◽

10.1007/s00423-021-02158-0 ◽

2021 ◽

Author(s):

Anas Taha ◽

Stephanie Taha-Mehlitz ◽

Victor E. Staartjes ◽

Fabian Lunger ◽

Severin Gloor ◽

...

Keyword(s):

Randomized Controlled Trial ◽

Colorectal Surgery ◽

Controlled Trial ◽

Anxiety And Depression ◽

Post Hoc Analysis ◽

Randomized Controlled ◽

Download Full-text